HHS enforcement discretion lets state pharmacies compound BPC-157 and other peptides amid rulemaking and legal challenges.

HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.

At AMCP Nexus 2026, payers said evidence, differentiation, and delivery now matter as much as FDA approval.

Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.

Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH

Telehealth surpasses out-of-state travel for abortion care in total-ban states in 2025, and a second study suggests telehealth and clinic patients differ.

UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.

Shields Health Solutions leaders say GLP-1 discontinuation is a support problem, not a medication problem, and pharmacist-led care can help close it.